Trial Profile
A Multicenter Study Comparing Efficacy and Safety of " Treat-and-Extend" Regimen Versus "Pro Re Nata" Regimen of Conbercept in Neovascular Age-related Macular Degeneration
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 17 May 2020 Planned End Date changed from 1 Dec 2018 to 1 Sep 2020.
- 17 May 2020 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2020.
- 17 May 2020 Status changed from not yet recruiting to active, no longer recruiting.